Vitamin D | Placebo | Adjusted incidence rate ratio | Adjusted relative risk | Adjusted mean difference | |||
---|---|---|---|---|---|---|---|
events (number) | Mean (95% CI) N = 23 | events (number) | Mean (95% CI) N = 24 | (95% CI) | (95% CI) | (95% CI) | |
URTI episodesa | |||||||
Incidence of URTIs/childb | |||||||
Verbal report - mean group rate/child | 98 | 4.48 (3.66, 5.49) | 95 | 4.12 (3.37, 5.03) | 1.24 (0.88, 1.75) | ||
Diary - mean group rate/childc | 44 | 3.63 (2.70, 4.87) | 64 | 4.24 (3.32, 5.42) | 0.92 (0.58, 1.49) | ||
Asthma exacerbations with URTIsa | |||||||
Incidence of exacerbations/childb | |||||||
Verbal report - mean group rate/child | 61 | 2.84 (2.20, 3.67) | 44 | 1.91 (1.42, 2.56) | 1.78 (1.10, 2.90) | ||
Diary - mean group rate/childc | 33 | 2.72 (1.93, 3.83) | 52 | 3.71 (2.83, 4.87) | 0.74 (0.43, 1.27) | ||
Intensity of asthma symptoms/episoded | |||||||
Diary - cumulative daily ADYC scorese, c | 34 | 11.0 (8.9, 13.2) | 54 | 12.5 (9.8, 15.1) | −0.7 (−3.7, 2.2) | ||
Duration of exacerbations in daysd | |||||||
Verbal report - mean group duration/episode | 57 | 7.6 (5.1, 10.0) | 43 | 7.4 (5.8, 9.0) | 1.0 (−3.0, 4.9) | ||
Diary - mean group duration/episoded, c | 34 | 5.1 (3.1, 7.0) | 54 | 5.2 (4.2, 6.2) | 0.3 (−1.9, 2.6) | ||
Intensity of β2-agonist use per episodef | |||||||
Diary - cumulative number of puffsc | 33 | 40.1 (30.4, 49.8) | 51 | 41.2 (32.1, 50.2) | −1.4 (− 13.5, 10.7) | ||
Impact on parents during URTIa | |||||||
Parental functional statusg | 35 | 3.3 (2.8, 3.9) | 49 | 3.2 (2.6, 3.8) | −0.1 (−1.3, 1.0) | ||
Workday-missed/episode | 36 | 1.0 (0.3, 1.7) | 50 | 1.7 (0.9, 2.5) | 0.1 (−1.2, 1.3) | ||
Healthcare service utilisation | |||||||
Courses of oral steroids/child | 22 | 0.96 (0.63, 1.45) | 19 | 0.79 (0.51, 1.24) | 1.21 (0.57, 2.57) | ||
Acute care visits for asthma/child | 24 | 1.04 (0.70, 1.56) | 24 | 1.00 (0.67, 1.49) | 1.34 (0.69, 2.63) | ||
Proportion (95% CI) | Proportion (95% CI) | ||||||
Subjects with ≥ 1 course of oral steroids | 14 | 61 (40, 78) % | 10 | 42 (24, 62) % | 1.36 (0.42, 4.47) | ||
Subjects with ≥ 1 acute care visit | 15 | 65 (44, 82) % | 12 | 50 (31, 69) % | 1.63 (0.51, 5.21) |